erlotinib

• 

Bevacizumab plus erlotinib shows antitumor activity in advanced papillary kidney cancer

By Sharon Deveson Kell|2025-10-07T08:32:56+00:007 Oct 2025|Drug treatments|

A recent phase 2 study, published in the New England [...]

Read More

Comments Off on Bevacizumab plus erlotinib shows antitumor activity in advanced papillary kidney cancer

• 

Combination therapy shows promise for hereditary papillary kidney cancer

By Sharon Deveson Kell|2025-06-20T15:30:06+00:0020 Jun 2025|Drug treatments|

Hereditary leiomyomatosis and renal cell carcinoma (HLRCC)-associated papillary RCC is [...]

Read More

Comments Off on Combination therapy shows promise for hereditary papillary kidney cancer

• 

ASCO 2020: Bevacizumab and erlotinib for advanced hereditary leiomyomatosis RCC and papillary RCC

By Sharon Kell|2020-06-02T14:18:52+00:002 Jun 2020|Uncategorized|

Results from a phase II study of bevacizumab and erlotinib [...]

Read More

Comments Off on ASCO 2020: Bevacizumab and erlotinib for advanced hereditary leiomyomatosis RCC and papillary RCC

• 

Bevacizumab plus erlotinib combination for advanced HLRCC

By Sharon Kell|2019-04-01T08:42:00+00:001 Apr 2019|Drug treatments|

A recent study, published in Cancer Research and Treatment in [...]

Read More

Comments Off on Bevacizumab plus erlotinib combination for advanced HLRCC

• 

Treatment for hereditary leiomyomatosis renal cell carcinoma (HLRCC): a rare and aggressive form of kidney cancer

By Sharon Kell|2017-04-10T11:46:46+00:0010 Apr 2017|Drug treatments, Subtypes of RCC|

In this video, Dr W. Marston Linehan, chief of the [...]

Read More

Comments Off on Treatment for hereditary leiomyomatosis renal cell carcinoma (HLRCC): a rare and aggressive form of kidney cancer